Use as an alternative immunomodulatory drug if tocilizumab is not available or not feasible to use (BIIa).
In the United States, the currently approved route of administration for<unk>  is SQ injection. In the REMAP-CAP trial, the SQ formulation was used to prepare the IV infusion.
Sarilumab
Raxibacumab
Idarucizumab
Tocilizumab
Baricitinib
Sotrovimab
Rituximab
Rasburicase